Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

The past three decades have witnessed a welcome expansion of the therapeutic armamentarium for the management of pulmonary arterial hypertension (PAH). However, against this backdrop, there have been some notable disappointments in drug development. Here we use these as case studies to emphasize the importance of informed drug target selection, the early evaluation of dose-response relationships in human studies, and the value of the deep phenotyping of patients in clinical studies to better understand inter-individual variation in patient response. The integration of "omics" technologies and advanced clinical imaging offer the potential to reduce the risk, and so cost, of drug development in PAH and bring much needed new medicines to those patients most likely to benefit with greater efficiency.

• Publication year

  2016

• Venue

  Pharmacology and Therapeutics

• Publication date

  2016-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2016.04.012PMID 27133570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Why Most Published Research Findings Are False

  2019cited by this paper
• Organs-on-chips at the frontiers of drug discovery

  2015cited by this paper
• Clinical development success rates for investigational drugs

  2014cited by this paper
• Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

  2013cited by this paper
• The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

  2012cited by this paper
• Statins and the Risk of Cancer After Heart Transplantation

  2012cited by this paper
• Atorvastatin in Pulmonary Arterial Hypertension (APATH) study

  2012cited by this paper
• Attenuation of Monocrotaline-induced Pulmonary Arterial Hypertension in Rats by Rosuvastatin

  2012cited by this paper
• Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

  2012cited by this paper
• Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension.

  2012cited by this paper
• Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia

  2012cited by this paper
• Vasoactive intestinal peptide in pulmonary arterial hypertension.

  2012cited by this paper
• Proof-Of-Concept Study To Investigate The Efficacy, Hemodynamics And Tolerability Of Terguride Vs. Placebo In Subjects With Pulmonary Arterial Hypertension: Results Of A Double Blind, Randomised, Prospective Phase IIa Study

  2012cited by this paper
• Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries

  2011cited by this paper
• Believe it or not: how much can we rely on published data on potential drug targets?

  2011cited by this paper
• The cost of drug development: a systematic review.

  2011cited by this paper
• CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system.

  2011cited by this paper
• C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.

  2011cited by this paper
• Why animal research needs to improve

  2011cited by this paper
• Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling.

  2011cited by this paper
• [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].

  2011cited by this paper
• Trial watch: Phase III and submission failures: 2007–2010

  2011cited by this paper
• Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery Hypertension

  2011cited by this paper
• Reliability of 'new drug target' claims called into question

  2011cited by this paper
• C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension.

  2011cited by this paper
• Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

  2011cited by this paper
• Simvastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1–dependent pathway

  2011cited by this paper
• [Atorvastatin attenuates hypoxic pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway].

  2011cited by this paper
• A call to reform the taxonomy of human disease

  2011cited by this paper
• Rodent models of pulmonary hypertension: harmonisation with the world health organisation’s categorisation of human PH

  2011cited by this paper
• Key role of the RhoA/Rho kinase system in pulmonary hypertension.

  2011cited by this paper
• Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.

  2011cited by this paper
• Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT

  2011cited by this paper
• PRX-08066, a Novel 5-Hydroxytryptamine Receptor 2B Antagonist, Reduces Monocrotaline-Induced Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Rats

  2010cited by this paper
• The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats.

  2010cited by this paper
• Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

  2010cited by this paper
• In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension.

  2010cited by this paper
• Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats

  2010cited by this paper
• Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats.

  2010cited by this paper
• Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

  2010cited by this paper
• Deconstructing the Drug Development Process: The New Face of Innovation

  2010cited by this paper
• Inhibitory Effects of Simvastatin on Platelet-derived Growth Factor Signaling in Pulmonary Artery Smooth Muscle Cells From Patients With Idiopathic Pulmonary Arterial Hypertension

  2010cited by this paper
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• Simvastatin as a treatment for pulmonary hypertension trial.

  2010cited by this paper
• EFFECTS OF ATORVASTATIN AND LOSARTAN ON MONOCROTALINE-INDUCED PULMONARY ARTERY REMODELING IN RATS: PP.29.138

  2009cited by this paper
• Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

  2009cited by this paper
• Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1.

  2009cited by this paper
• Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats

  2009cited by this paper
• Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.

  2009cited by this paper
• Simvastatin and sildenafil combine to attenuate pulmonary hypertension

  2009cited by this paper
• 3-Hydroxy-3-Methylglutaryl-COA Reductase Inhibitors and Phosphodiesterase Type V Inhibitors Attenuate Right Ventricular Pressure and Remodeling in a Rat Model of Pulmonary Hypertension

  2009cited by this paper
• [Simvastatin prevents the development of pulmonary hypertension in the rats through reduction of inflammation].

  2009cited by this paper
• VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population

  2009cited by this paper
• Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors.

  2008cited by this paper
• Rosuvastatin Provides Pleiotropic Protection Against Pulmonary Hypertension, Right Ventricular Hypertrophy and Coronary Endothelial Dysfunction in Rats

  2008cited by this paper
• Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension

  2008cited by this paper
• The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease.

  2008cited by this paper
• Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

  2008cited by this paper
• Inhalation of vasoactive intestinal peptide in pulmonary hypertension

  2008cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• [Expression of connective tissue growth factor and its down-regulation by simvastatin administration in pulmonary hypertensive rats].

  2008cited by this paper
• Effect of Tryptophan Hydroxylase 1 Deficiency on the Development of Hypoxia-Induced Pulmonary Hypertension

  2007cited by this paper
• Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice.

  2007cited by this paper
• Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin.

  2007cited by this paper
• Regression of chronic hypoxic pulmonary hypertension by simvastatin.

  2007cited by this paper
• [Effect of simvastatin on rat pulmonary hypertension induced by high pulmonary blood flow and injected monocrotaline].

  2007cited by this paper
• Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension

  2007cited by this paper
• Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene

  2007cited by this paper
• Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.

  2007cited by this paper
• Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin.

  2007cited by this paper
• The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

  2006cited by this paper
• Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

  2006cited by this paper
• Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension.

  2006cited by this paper
• Serotonin Inhibits Voltage-Gated K+ Currents in Pulmonary Artery Smooth Muscle Cells: Role of 5-HT2A Receptors, Caveolin-1, and KV1.5 Channel Internalization

  2006cited by this paper
• Genetic association of the serotonin transporter in pulmonary arterial hypertension.

  2006cited by this paper
• The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

  2006cited by this paper
• Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking.

  2006cited by this paper
• Targeting Tyrosine Kinases in Cancer: The Second Wave

  2006cited by this paper
• Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats

  2005cited by this paper
• Functional Interactions between 5-Hydroxytryptamine Receptors and the Serotonin Transporter in Pulmonary Arteries

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Why Most Published Research Findings Are False

  2005cited by this paper
• Pharmacokinetics of oral terguride in patients with a prolactinoma

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Mendelian randomization: prospects, potentials, and limitations.

  2004cited by this paper
• Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter.

  2004cited by this paper
• 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

  2003cited by this paper
• Attenuation of chronic hypoxic pulmonary hypertension by simvastatin.

  2003cited by this paper
• Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

  2003cited by this paper
• Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.

  2003cited by this paper
• Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.

  2003cited by this paper
• Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells

  2003cited by this paper
• Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.

  2003cited by this paper
• Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.

  2002cited by this paper
• Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

  2002cited by this paper
• Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

  2002cited by this paper
• Contribution of the 5-HT1B Receptor to Hypoxia-Induced Pulmonary Hypertension: Converging Evidence Using 5-HT1B-Receptor Knockout Mice and the 5-HT1B/1D-Receptor Antagonist GR127935

  2001cited by this paper
• 5-HT1B receptor augmented 5-HT vasoconstrictor response of pulmonary artery in monocrotaline-induced pulmonary hypertensive rats.

  2001cited by this paper
• Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

  2001cited by this paper
• Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension

  2000cited by this paper

• Growth factors involved in vascular remodeling in pulmonary arterial hypertension

  2025cites this paper
• [In vitro activity of human recombinant interferon gamma against SARS-CoV-2 virus].

  2023cites this paper
• Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation

  2023cites this paper
• Effects of adjuvant ozone autohemotherapy combined with routine treatment on clinical and paraclinical features of mechanically ventilated COVID-19 patients in the intensive care unit: a pilot randomized controlled trial

  2023cites this paper
• 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.

  2023cites this paper
• The sine transform is the sine qua non of the pulmonary and systemic pressure relationship

  2023cites this paper
• The Platelet-Derived Growth Factor Pathway in Pulmonary Arterial Hypertension: Still an Interesting Target?

  2022cites this paper
• A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)

  2022cites this paper
• DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy

  2021cites this paper
• Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2021cites this paper
• [In vitro activity of human recombinant alpha-2b interferon against SARS-CoV-2 virus].

  2021cites this paper
• A systematic review protocol of the antiviral activity of chloroquine and hydroxychloroquine against COVID-19.

  2020cites this paper
• Current and future treatments of pulmonary arterial hypertension

  2020influential citation
• Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension

  2020cites this paper
• Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

  2020cites this paper
• Blocking properties of terguride at the 5-HT2 receptor subtypes mediating cardiovascular responses in the rat.

  2020cites this paper
• Drug Repositioning for COVID-19

  2020cites this paper
• Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2

  2020cites this paper
• Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application

  2020cites this paper
• Beyond the Genome: Challenges and Potential for Epigenetics-driven Therapeutic Approaches in Pulmonary Arterial Hypertension.

  2020cites this paper
• Toward Better Reproducibility in Experimental Research on New Agents for Pulmonary Hypertension. An Analysis of Data from Four Hundred Animal Studies

  2020cites this paper
• Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2

  2020cites this paper
• Genomics and personalised medicine : diagnostics, deep phenotyping and pharmacogenomics in cohorts of rare disease patients

  2019cites this paper
• Rigor and reproducibility in rodent behavioral research.

  2019cites this paper
• Systems Analysis of the Human Pulmonary Arterial Hypertension Lung Transcriptome.

  2019cites this paper
• Clinical trial design and new therapies for pulmonary arterial hypertension

  2019cites this paper
• Platelet‐derived growth factor up‐regulates Ca2+‐sensing receptors in idiopathic pulmonary arterial hypertension

  2019cites this paper
• Towards improved pharmacotherapy in pulmonary arterial hypertension. Can diet play a role?

  2019cites this paper
• MicroRNA‑132 mediates proliferation and migration of pulmonary smooth muscle cells via targeting PTEN.

  2019cites this paper
• Rationale for Targeting the Serotonin System as a Treatment of Pulmonary Hypertension

  2019influential citation
• Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension

  2019cites this paper
• Pulmonary vasodilators: Latest evidence and outcomes in the perioperative setting.

  2018cites this paper
• The role of Tumour Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) in Pulmonary Arterial Hypertension

  2018cites this paper
• Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension

  2018influential citation
• Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy?

  2018cites this paper
• Apoptosis Signal-Regulating Kinase 1 Inhibition in Pulmonary Hypertension. Too Much to ASK?

  2017cites this paper
• Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

  2017cites this paper
• Pulmonary arterial hypertension – progress in understanding the disease and prioritizing strategies for drug development

  2017cites this paper
• Corneal Endothelial Cell Integrity in Precut Human Donor Corneas Enhanced by Autocrine Vasoactive Intestinal Peptide

  2017cites this paper
• Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

  2017cites this paper
• Pulmonary arterial hypertension: are we close to the success?

  2017cites this paper
• Nobiletin protects against monocrotaline-induced pulmonary arterial hypertension in rats by regulating Src / STAT 3 signaling pathway

  2017cites this paper
• Future perspectives in pulmonary arterial hypertension

  2016cites this paper